VivoSeq
Other

Hyperinsulinism

12

Pipeline Programs↗

6

Active Trials↗

7

Companies Involved↗

Hyperinsulinism is an emerging landscape with 12 programs across 7 companies. The most active players are Prism Pharmaceuticals, Xeris Pharmaceuticals, Hanmi Pharmaceutical Company Limited. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

92/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Prism Pharmaceuticals

1 program

Phase 1X

Xeris Pharmaceuticals

1 program

Phase 2Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited

1 program

Phase 2E

Eiger BioPharmaceuticals

1 program

Phase 2Zealand Pharma logo

Zealand Pharma

1 program

Phase 3Ipsen logo

Ipsen

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

12 of 14 classified programs — the dominant modality here.

14%ALL OTHERSPeptide214%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

19

clinical trials

Completed12 · 63%
Recruiting5 · 26%
Active, not recruiting1 · 5%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

19 trials

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
Recruiting·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 2·NCT04732416·16 enrolled
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Recruiting·RRezolute·Phase 3·NCT06881992·16 enrolled
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
Recruiting·CCook Children's Health Care System·Phase 1·NCT02021604·250 enrolled
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
Recruiting·—·Phase 2·NCT04205604·50 enrolled
Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism
Recruiting·WWashington University School of Medicine·Phase 2·NCT05088798·100 enrolled
RZ358 Treatment for Congenital Hyperinsulinism
Active, not recruiting·RRezolute·Phase 3·NCT06208215·56 enrolled
Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
Completed·—·N/A·NCT00004699·8 enrolled
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
Completed·XXOMA (US) LLC·Phase 2·NCT02604485·10 enrolled
Sandostatine® LP and Hyperinsulinism
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00987168·10 enrolled
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
Completed·XXeris Pharmaceuticals·Phase 2·NCT02937558·5 enrolled
An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
Completed·RRezolute·Phase 2·NCT04538989·23 enrolled
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
Completed·Zealand Pharma logoZealand Pharma·Phase 3·NCT03777176·32 enrolled
Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
Completed·FFDA Office of Orphan Products Development·N/A·NCT00004825·10 enrolled
Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism
Completed·—·Phase 2·NCT00004700·16 enrolled
Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
Completed·—·Phase 2·NCT00674440·106 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)